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Osteoporotic fractures (fragility fractures) are more frequent
in postmenopausal women than in older men [1]. However,
osteoporosis in men is one of the major and the most
neglected public health problems for several reasons.
First, morbidity, mortality, and loss of independence
after major fragility fracture are greater in men than women
[2, 3]. The interpretation of data concerning mortality
after fragility fracture should be, however, cautious. As life
expectancyis lowerinmenthanwomen,it is not appropriate
to compare mortality after hip fracture between men and
women of the same age. Therefore, it is important that,
for a given age, the additional increase in mortality after a
hip fracture is greater in men than women [4]. In addition,
the fraction of the potential time of life lost after a hip
fracture (taking into account the sex-speciﬁc life expectancy)
is greater in men than women [5]. Thus, these studies show
that the mortality after a hip fracture is really higher in men
than in women.
Secondly, the number of osteoporotic fractures in men
increases rapidly. The overall number of fractures is on the
rise because the elderly population increases due to the
lengthening of the lifespan. However, several studies have
shown that the age-speciﬁc incidence of major osteoporotic
fractures in postmenopausal women, especially hip fracture,
has been slightly, but consistently, decreasing for the last 15
years [6–8]. Such trends have been observed in North Amer-
ica, Australia, and several European countries. By contrast,
in these countries, the age-speciﬁc incidence of hip fracture
in men decreased less than in women or even remained
stable [8–10]. In addition, in some European countries and
in Japan, age-speciﬁc hip fracture incidence continues to
increase in both sexes [11, 12]. Therefore, over the next
decades, the number of osteoporotic fractures is expected to
increasefasterinmenthaninwomen.Consequently,fragility
fractures in men will constitute higher percentage of all the
osteoporotic fractures than they do now.
Thirdly, the identiﬁcation of men at high risk of fracture
isnot satisfactory.Increasing age,history offragility fracture,
and low bone mineral density (BMD) measured by dual
energy X-ray absorptiometry (DXA) are important risk fac-
torsoffracture.Nevertheless,only20%ofmenwhosustaina
hipfractureormajorosteoporoticfracturehaveosteoporosis
diagnosed byDXAusing thesex-speciﬁcT-score < −2.5,half
as many compared with women from the same cohort [13–
15].
The diagnostic criteria of osteoporosis in men are a
matter of controversy. The International Society for Clinical
Densitometry (ISCD) recommends sex-speciﬁc T-score <
−2.5 [16]. By contrast, International Osteoporosis (IOF)
recommends the threshold corresponding to T-score = −2.5
in premenopausal women [17]. It corresponds to a T-score
of approximately −2.75 compared with peak BMD in young
men. The justiﬁcation for using a female-based threshold
is that the risk of fracture is similar in both sexes for the
same absolute BMD, not for the same sex-speciﬁc T-score.
If we accept the threshold recommended by ISCD, men with
lower risk of fracture will be treated and we will have to treat
more men to avoid one fracture. If we accept the threshold
recommended by IOF, fewer men will be treated and fewer
fractures will be avoided. Does it mean that the threshold of
ISCD should be preferred? Not necessarily. Aside from the
individual fracture risk, there is also variation from country2 Journal of Osteoporosis
to country in the willingness to pay for therapy and in the
choice of the treatment criterion. If the sex-speciﬁc T-score =
−2.5 identiﬁes men at a lower risk of fracture than women,
the health authorities may refuse the reimbursement of any
antiosteoporotic treatment in men. If the IOF threshold is
recommended in these countries, it will be easier to obtain
the reimbursement for the osteoporosis treatment in men.
Fewer men will be treated, but at least, it will be possible to
reduce the risk of fracture in those who have the most severe
osteoporosis and the highest risk of fracture.
An additional problem is that other bone parameters do
not provide much improvement in the prediction of frac-
ture in men. Classical biochemical bone turnover markers
(BTMs) are not predictive of fracture in the multivariable
models adjusted for BMD [18, 19]. Ultrasound parameters
predict fractures in men similarly to BMD, but their
joint use does not improve fracture prediction compared
with BMD alone [20]. Quantitative computed tomography
(QCT) predicts hip fracture, but not better than DXA alone
[21]. Young healthy men with prevalent fractures had lower
cortical bone volume assessed by peripheral QCT than men
without fracture [22]. However, these analyses were not
adjusted for BMD measured by DXA. High-resolution
peripheral quantitative computed tomography (HR-pQCT)
allows assessment of bone microarchitecture at the distal
radius and tibia. Men with vertebral fractures had thinner
cortex and lower cortical volumetric BMD assessed by HR-
pQCT compared with men without vertebral fracture, even
after adjustment for BMD measured by DXA [23]. However,
these cross-sectional data have to be conﬁrmed in the
prospective studies.
Severalstudieshaveassessedotherapproachesthataimed
to improve fracture prediction in men. The FRAX algorithm
is a signiﬁcant landmark in the assessment of the individual
risk of fracture [24]. It takes into account several risk factors,
which determine bone fragility, for example, history of
fracture, parental history of hip fracture, corticotherapy, and
so forth. Another algorithm is the Garvan nomogram [25].
It takes into account history of fractures and that of falls.
Falls, especially multiple falls, seem to be associated with
a substantial increase in the risk of peripheral fracture in
the elderly men [26]. However, both FRAX and the Garvan
nomogram have been introduced only recently and few
studies assessed their utility in men [27, 28].
Limited data suggest an association between bone size
and risk of fracture. Low bone width was associated with
higher risk of fracture independently of BMD [29]. History
of fracture was associated with lower cross-sectional area
(CSA) measured by peripheral QCT [23]. However, no
method of measurement of bone width or CSA could be
recommended currently for the clinical practice. Several
studiesshowedthatlongerfemoralneckaxisandwiderneck-
shaft angle were associated with higher risk of hip fracture,
mainly cervical fracture [30, 31]. However, these associations
were weak and not consistent between the investigated
groups.
More and more studies suggest utility of the ﬁnite
element analysis (FEA) for fracture prediction in men. The
load-to-strength ratio remained signiﬁcantly associated with
the risk of hip fracture after adjustment for BMD [32]. More
recently, vertebral compressive strength improved vertebral
fracture risk assessment in comparison with DXA-measured
BMD [33]. However, FEA is not available in the clinical
practice.
Serum and urinary levels of C-terminal telopeptide of
type I collagen did not predict fracture after adjustment for
BMD in men. By contrast, measurement of serum levels of
native,nonisomerizedformofCTX-I(α-CTX-I)andofbeta-
isomerized form (β-CTX-I) showed that higher α-CTX-I/β-
CTX-I ratio is associated with higher risk of fracture in men
[34]. However, it is not clear if the increased α-CTX-I/β-
CTX-I ratio reﬂects higher bone turnover rate or an intrinsic
defect of posttranslational modiﬁcations of bone collagen.
The use of these measures has not been shown to improve
the prediction of fracture or the management of care in men
with osteoporosis.
In most of the cohorts, decreased levels of total or bi-
oavailable 17β-estradiol were associated with higher risk of
fragility fracture in men [35–37]. However the analyses were
not systematically adjusted for BMD. Decreased serum level
of 25-hydroxycholecalciferol was associated with higher risk
of hip fracture in American men aged >65 and with higher
risk of clinical fracture in Swedish men aged >65 [38, 39].
However, this association was markedly attenuated after
adjustment for hip BMD [38]. Low serum level of insulin-
like growth factor I (IGF-I) was associated with a higher
risk of ostoporotic fracture in men, also after adjustment
for BMD [40]. The potential mechanism underlying this
association is not clear. This observation is, however, inter-
esting because serum IGF-I concentration was not correlated
with BMD in older men [41, 42]. Finally, increased level
of ﬁbroblast growth factor 23 was associated with higher
risk of nonspine fracture in the elderly men, even after
adjustmentforconfoundersincludingBMDandparathyroid
hormoneconcentration[43].However,theexactmechanism
underlying this association has not been elucidated.
Thus, FRAX appears to improve the assessment of the
fracture risk in both sexes; however, it needs to be veriﬁed
in a higher number of cohorts of men. By contrast, other
available studies do not provide reliable methods permitting
to identify with a satisfactory probability older men at high
risk of fracture.
Fourthly, fewer studies concern the antiosteoporotic
treatment in older men compared with the studies carried
out in postmenopausal women. Most studies assessed only
changes in BMD measured by DXA and in the BTM
levels induced by antiosteoporotic treatment [44–48]. Then,
the antifracture eﬃcacy of the investigated medications in
men is inferred indirectly from these bridging studies by
comparing their results with the data obtained previously
in postmenopausal women. By contrast, few studies assessed
the antifracture eﬃcacy of the antiosteoporotic therapies
in men [48–52]. Moreover, some of these studies were not
powered to this type of analysis. Some of these studies were
observationalsurveys,notrandomizedpharmaceuticaltrials.
The eﬀect of the antiosteoporotic medications on the risk of
fracture in men was assessed speciﬁcally only in few studies.Journal of Osteoporosis 3
The antifracture eﬃcacy of denosumab and toremifene has
been investigated in men receiving androgen-deprivation
therapy for prostate cancer [53–55]. In older osteoporotic
men, zoledronic acid decreased signiﬁcantly the incidence of
vertebral fractures [56].
Fifthly, even men with an increase in fracture risk are
rarely treated. In men, the parameter that indicates higher
risk of fracture most consistently in epidemiological studies
is prevalent fragility fracture [26, 57]. A history of osteo-
porotic fracture is associated with a two- to fourfold higher
risk of another osteoporotic fracture. This is a very similar
situation to thatfound in postmenopausal women. However,
about 50 percent of women who sustained fragility fracture
beneﬁt from bone densitometry and/or antiosteoporotic
treatment [58–60]. By contrast, less than 10 percent of
men who sustained an osteoporotic fracture will have bone
densitometry and/or osteoporotic treatment [58–60]. In
some studies, only 1 out of 20 men having sustained a hip
fracture (and were hospitalized for this fracture) beneﬁted
from bone densitometry and/or antiosteoporotic treatment
[60]. Even men receiving chronic glucocorticoid therapy or
androgendeprivationtherapyarenotsystematicallyscreened
and, whenever appropriate, treated for osteoporosis [61, 62].
In conclusion, on one hand, osteoporosis in older men
is a major public health problem. The number of fragility
fractures in men is rapidly increasing, the consequences of
these fractures are more severe in men than in women,
and the identiﬁcation of men at high risk of fracture is
suboptimal. On the other hand, osteoporosis in older men
should be considered a neglected public health problem.
There are fewer data on the appropriate measures to assess
fracture risk, less information on the antifracture eﬃcacy of
the available medications in men than in women, and only
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